Abstract

FORMULATION AND EVALUATION OF MEDICATED CHEWING GUM

Dr. Sapna Desai*, Yagnesh Modi, Maitri Shah, Sakshi Vani, Riya Solanki, Jayshri Padhiyar, Dr. Sohan Patel, Dr. Dhananjay Meshram

.

Abstract

Aim: Medicated Chewing Gum (MCG) is an innovative drug delivery method that utilizes chewing to dispense Gallic Acid, the key active component. This compound is employed for its localized effects or for absorption through the buccal mucosa. The main objective of MCG is to alleviate anxiety by enabling a regulated release of the active ingredient. Method: MCGs were formulated using conventional techniques with Gallic Acid serving as the active element. Two gum base polymers, Polyvinylpyrrolidone (PVP) and Eudragit L-100, were utilized to ensure the desired texture and chewiness. The products were evaluated based on pre-compression parameters (angle of repose, bulk density, tapped density, compressibility index, and Hausner’s ratio) and post-compression parameters (weight variation, moisture content, elasticity, friability, drug content, in-vitro drug release, and antioxidant activity). The antioxidant potential was measured using the Ferric Reducing Antioxidant Power (FRAP) assay. Results: Four batches of formulations were prepared, with Batch 2 showing the best performance in both pre-compression and post-compression tests. The FRAP assay displayed antioxidant activity at various concentrations (20, 40, 60, 80, 100 μg/mL), yielding FRAP values of 0.4106, 3.4814, 4.2341, 4.2479, and 4.6686, respectively. The IC50 value for Gallic Acid was found to be 4.4475 μg/mL, while Ascorbic Acid, the reference drug, had an IC50 of 4.594 μg/mL. Conclusion: The optimized formulation of Medicated Chewing Gum containing Gallic Acid shows significant potential in providing anxiety-reducing effects, backed by favourable physical attributes, effective drug release characteristics, and strong antioxidant activity.

Keywords: Medicated chewing gum, Gallic acid, Anxiety, Antioxidant.